STOCK TITAN
  1. Home
  2. News
  3. ABOS

Acumen Pharmaceuticals (ABOS) Stock News

ABOS Nasdaq

Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.

Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.

Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.

News

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
none
-
News

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
conferences
-
News

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences earnings
News

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
-
News

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.73%
Tags
conferences
-
News

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.84%
Tags
clinical trial
News

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences clinical trial
-
News

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
conferences
-
News

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
conferences
News

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings

FAQ

What is the current stock price of Acumen Pharmaceuticals (ABOS)?

The current stock price of Acumen Pharmaceuticals (ABOS) is $2.2 as of July 27, 2026.

What is the market cap of Acumen Pharmaceuticals (ABOS)?

The market cap of Acumen Pharmaceuticals (ABOS) is approximately 153.8M.